GeneDx (WGS) to Release Quarterly Earnings on Tuesday

GeneDx (NASDAQ:WGS) is scheduled to be releasing its earnings data before the market opens on Tuesday, October 29th. Analysts expect GeneDx to post earnings of ($0.19) per share for the quarter. GeneDx has set its FY 2024 guidance at EPS.Individual interested in registering for the company’s earnings conference call can do so using this link.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Tuesday, July 30th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.15. The business had revenue of $70.51 million during the quarter, compared to analyst estimates of $58.90 million. GeneDx had a negative return on equity of 22.71% and a negative net margin of 48.21%. On average, analysts expect GeneDx to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

GeneDx Stock Down 3.1 %

Shares of GeneDx stock opened at $58.19 on Tuesday. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.38 and a quick ratio of 2.22. The company has a 50-day moving average of $41.34 and a 200 day moving average of $29.89. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -11.23 and a beta of 2.32. GeneDx has a 1 year low of $1.16 and a 1 year high of $61.96.

Insider Activity at GeneDx

In related news, major shareholder Opko Health, Inc. sold 100,000 shares of the stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $31.82, for a total transaction of $3,182,000.00. Following the transaction, the insider now owns 2,871,570 shares in the company, valued at $91,373,357.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, major shareholder Opko Health, Inc. sold 100,000 shares of the company’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $31.82, for a total transaction of $3,182,000.00. Following the completion of the sale, the insider now owns 2,871,570 shares in the company, valued at approximately $91,373,357.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Katherine Stueland sold 2,154 shares of the firm’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $33.54, for a total value of $72,245.16. Following the completion of the transaction, the chief executive officer now directly owns 92,550 shares in the company, valued at $3,104,127. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 543,668 shares of company stock valued at $18,104,988 over the last ninety days. Insiders own 28.10% of the company’s stock.

Analysts Set New Price Targets

WGS has been the topic of a number of analyst reports. BTIG Research boosted their price target on GeneDx from $35.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Wells Fargo & Company initiated coverage on GeneDx in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $34.00 target price on the stock. Craig Hallum lifted their price target on GeneDx from $43.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. The Goldman Sachs Group upped their price target on shares of GeneDx from $32.00 to $54.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 16th. Finally, TD Cowen raised their price objective on shares of GeneDx from $46.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, GeneDx presently has an average rating of “Moderate Buy” and an average price target of $41.67.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.